Nanostics Welcomes New Board Member Mike SchoenbergerForward Momentum2022-02-05T03:16:10+00:00
Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site
Forward Momentum2022-01-04T19:06:51+00:00PR: Nanostics announced the re-opening of their clinical validation study testing ClarityDX Prostate in a real-world setting. The study is also greatly benefiting from further expansion into the US with the addition of a new patient recruitment site at an award-winning United States clinical research institution. ClarityDX Prostate is a novel liquid biopsy test for the early diagnosis of clinically significant prostate cancer. Nanostics is excited to work with this Partner to reach the recruitment numbers and diversity goals of the clinical study.
Nanostics is Developing and Validating a Simple Blood Test to Predict Severity of COVID-19 Disease in SARS-CoV-2 Positive Patients
Forward Momentum2022-01-04T19:08:02+00:00PR today: Nanostics to use ClarityDX platform to develop & validate a blood test to predict COVID-19 severity in SARS-CoV-2 patients; with Canadian BioSample Repository in Alberta and Century Clinical Research Institute in Florida.
Alberta Impact with Bryce Lambert, Episode 3, ‘Future of Health’ DynaLIFE Accelerator Lab; benefits of this amazing Medical Lab program
Forward Momentum2022-01-04T19:08:38+00:00Your technology’s proven in an academic lab⎯now you want it adopted into the healthcare system. The DynaLIFE Accelerator helps startups develop and validate tests in a real-world setting.
Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT03957252
Forward Momentum2022-01-04T19:09:09+00:00Clinical study to validate ClarityDX Prostate as a reflex test to high PSA levels to refine prediction of clinically significant prostate cancer has begun in a prospective cohort of 2800 men.
CBC News-Biotech firm recruiting Yukon men for trial, Prostate cancer group says it could save lives
Forward Momentum2022-01-04T19:09:39+00:00Alberta-based Nanostics is hoping to recruit 200 Yukoners to the clinical validation study testing ClarityDX Prostate in a real-world setting.
CKRW 96.1 FM Radio-Cancer Study Comes to the Yukon
Forward Momentum2022-01-04T19:10:13+00:00The Yukon Ride for Dad, which raises money for prostate cancer awareness and research, is making a substantial investment in Nanostic’s research into diagnostic testing for prostate cancer.
Movember and Alberta Cancer Foundation campaigns boost prostate cancer screening study
Forward Momentum2022-01-04T19:11:01+00:00News Medical Lifesciences – ClarityDX Prostate cancer diagnostic test validation study gets a boost in recruitment thanks to concurrent fundraising campaigns.
ClarityDX Prostate clinical validation study is expanding into the US with Century Clinical Research, Inc.
Forward Momentum2022-01-04T19:11:32+00:00The Nanostics & APCaRI co-sponsored ClarityDX Prostate clinical validation study is expanding into the US by opening the Daytona Beach, Florida Century Clinical Research, Inc. recruitment site.
Nanostics featured on Alberta Impact Episode 5 with Bryce Lambert
Forward Momentum2022-01-04T19:12:04+00:001 of 7 Canadian men is diagnosed with prostate cancer each year. We cannot emphasize enough on how important it is to get tested each year. Nanostics has come up with a non-invasive diagnostic test to bring clarity to healthcare decisions. Their core technology is in development to be able to diagnose prostate cancer from a simple blood test.
